title: Temozolomide-associated organizing pneumonitis.
abstract: Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. maldonado.fabien@mayo.edu
authors.forename: Fabien
authors.initials: F
authors.lastname: Maldonado
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Limper
authors.forename: Kaiser G
authors.initials: KG
authors.lastname: Lim
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Aubrey
mesh_terms: D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide